Truist keeps Buy on Regeneron, lifts target to $780
Alpha Vantage · GuruFocus · · AI-summarised by FinFlash
Truist Securities reiterated a Buy rating on Regeneron Pharmaceuticals and raised its price target to $780.00, citing a positive outlook. GuruFocus data shows REGN undervalued by 18.1% with a GF Score of 87, supported by financial strength and profitability. Analyst consensus targets average $853.19 versus a $726.47 price, implying 17.4% upside, with ratings split at 17 Buy, 9 Hold and 1 Sell.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.